Alterity Therapeutics (ATHE) Revenue (2013 - 2019)
Alterity Therapeutics (ATHE) posted Revenue of $1.3 million for Q4 2019, up 1441.66% on a QoQ basis from $82212.4 in Q4 2015.
Powered by 
Analysis
Alterity Therapeutics (ATHE) Revenue (2013 - 2019) Analysis & Trends
Alterity Therapeutics has reported Revenue for 3 years, with the latest figure at $1.3 million in Q4 2019.
- On a quarterly basis, Revenue changed N/A year-over-year to $1.3 million in Q4 2019; TTM through Dec 2019 was $1.7 million, a N/A change from a year earlier, with the FY2018 full-year figure at $155994.3, up 56.25% from the prior year.
- Revenue was $1.3 million for Q4 2019 at Alterity Therapeutics, up from $82212.4 in the prior quarter.
- The five-year high for Revenue was $1.3 million in Q4 2019, with the low at $82212.4 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Alterity Therapeutics | 72.80 Mn | 72.80 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 1.27 Mn |
| Dec 31, 2015 | 82,212.36 |
| Dec 31, 2013 | 48,849.02 |